Dr. Suresh de Silva
Chief Scientific Officer, GALDEN Platform at Shattuck Labs
Dr. Suresh de Silva has served as Chief Scientific Officer of the GADLEN technology platform at Shattuck Labs, Inc. since January, 2023. He Previously served as Vice President of Product Development from 2018-2022 and as our Executive Director of Research and Development from 2017-2018. Suresh joined Shattuck in 2017 and is one of the scientific co-inventors of the ARC technology platform and co-led the preclinical development of SL-279252 and SL-172154. Prior to joining Shattuck, Suresh served as the Director of Research and Development at Heat Biologics, Inc. in Durham, NC, where he led external research collaborations and co-developed the ComPact cell-based vaccine platform. Suresh’s research experience spans the fields of gene therapy, infectious disease (HIV) and cancer immunotherapy where he has co-authored numerous publications. Suresh received his M.S. and Ph.D. from the University of Rochester, New York, and subsequently completed a successful post-doctoral fellowship at The Ohio State University.
Got a question for Dr. Suresh de Silva?
Get in touch using the contact form linked here and we’ll get back to you shortly
Bifunctional Fc-Based Fusion Protein Therapies: From Concept to the Clinic - Session 2
